Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) will present at the Leerink Partners Global Healthcare Conference in Miami from March 9-11, 2026. CEO Faraz Ali will join a fireside chat on March 9, 2026 at 1:00 pm ET. A live webcast will stream via the company Investors site, with an archived replay available for approximately 30 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
TNYA fell 7.77% while peers were mixed: TRDA -7.73%, CGTX -6.03%, but SLN and SLS gained modestly and TLSA was flat, suggesting stock-specific pressure rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Strategic update | Positive | -1.0% | Outlined 2026 priorities, clinical milestones and funding runway through mid-2027. |
| Dec 12 | Equity offering | Negative | -37.5% | Priced public offering of 50M units at $1.20 with attached warrants. |
| Dec 11 | Offering proposal | Negative | -37.5% | Announced intent to offer stock and warrant units under existing Form S-3. |
| Dec 11 | Clinical hold lifted | Positive | -37.5% | FDA removed clinical hold on MyPEAK-1 trial of TN-201 after protocol changes. |
| Dec 11 | Clinical data update | Positive | -37.5% | Reported positive interim RIDGE-1 TN-401 data with PVC reductions and tolerability. |
Recent history shows predominantly negative price reactions, including sharp declines on both dilutive offerings and ostensibly positive clinical/regulatory updates.
Over the last several months, Tenaya reported positive clinical and strategic updates alongside dilutive financing. In December 2025, a proposed and then priced public offering coincided with -37.5% moves, while the lifting of an FDA clinical hold for TN-201 and positive interim RIDGE-1 data also saw -37.5% reactions. A January 9, 2026 update outlining 2026 milestones and funding through mid-2027 saw a more modest -0.96% move. Today’s conference participation fits within this backdrop of volatile responses to news.
Market Pulse Summary
This announcement highlights Tenaya’s participation in a major healthcare conference, with a fireside chat on March 9, 2026 and a webcast replay available for 30 days. In recent months, the company has combined strategic updates, financings, and gene-therapy data releases, some of which coincided with sharp price moves. Investors may focus on upcoming clinical readouts, funding runway milestones, and any new disclosures that emerge around conference appearances.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat on Monday, March 9, 2026, at 1:00 pm ET.
The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
When is Tenaya Therapeutics (TNYA) presenting at the Leerink Partners Global Healthcare Conference 2026?
How can investors watch the Tenaya Therapeutics (TNYA) fireside chat on March 9, 2026?
Will Tenaya Therapeutics (TNYA) provide a replay of the conference webcast and for how long?
Who from Tenaya Therapeutics (TNYA) is speaking at the Leerink Partners Global Healthcare Conference 2026?
Where and when is the Leerink Partners Global Healthcare Conference 2026 taking place for Tenaya Therapeutics (TNYA)?
